12:00 AM
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Onyx, Bayer preclinical data

In vitro studies on colorectal cancer cells with V600E BRAF mutations showed that Nexavar restored the sensitivity of the mutated cells to EGFR-targeting mAbs Erbitux cetuximab and Vectibix panitumumab. Nexavar combined with Erbitux substantially induced cell death in...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >